Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital
- 94 Downloads
Vancomycin is one of the commonly used anti-microbial drugs in intensive care units (ICUs). Guidelines recommend maintaining therapeutic trough levels of vancomycin (10–20 mg/L). The success of achieving the recommended therapeutic concentration of vancomycin is influenced by several factors, and this is even more complex in children, particularly those admitted in the ICU. Hence, we carried out the present study in children admitted in the ICU who were administered vancomycin.
We carried out a chart review of children admitted in the paediatric ICU unit of a tertiary care hospital over a period of 3 years. Information on their demographic factors, diagnoses, duration of hospital stay, vancomycin treatment (dose, frequency and time of administration) and concomitant drugs, and vancomycin trough levels were retrieved. Descriptive statistics were used for representing the demographic factors, and multivariable logistic regression analyses were carried out to assess the determining factors.
One-hundred and two children were identified, of whom 13 had renal dysfunction. Two-hundred and fifty-two vancomycin trough levels were available, of which only 25% were observed in the recommended range (10–20 mg/L) amongst patients without any renal dysfunction and 22% amongst patients with renal dysfunction. Vancomycin was administered intravenously at an average [standard deviation (SD)] dose (mg/dose) of 13 (3.9) mostly either thrice or four times daily. Even in patients receiving vancomycin as a definitive therapy, only 40.9% achieved the recommended trough levels. Lower trough levels were associated with an increased risk of mortality. Nearly 4% of the levels were above 20 mg/L (toxic range). Seven children were suspected to have acute kidney injury (AKI) during the course of therapy where the cumulative vancomycin dose and mortality rate was higher. Only one serum vancomycin level during augmented renal clearance was observed in the recommended range. All the patients received at least one concomitant drug that either had nephrotoxic potential or predominant renal elimination, and use of a greater number of such drugs was associated with an increased risk of AKI.
The current vancomycin dosing strategy is ineffective in achieving therapeutic trough levels in children admitted to the ICU. Sub-therapeutic vancomycin trough levels significantly increase the risk of mortality.
We thank the Research Technical Support Team in the Ministry of Health, Bahrain, for their ethics approval for carrying out this study.
Compliance with Ethical Standards
No funding was obtained.
Conflict of interest
The authors, K. Sridharan, A. Al-Daylami, R. Ajjawi and H.A.M. Al Ajooz, do not have any conflicts of interest to declare.
- 1.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.CrossRefPubMedGoogle Scholar
- 2.Abad CL, Pulia MS, Krupp A, Safdar N. Reducing transmission of methicillin resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in the ICU—an update on prevention and infection control practices. JCOM. 2014;21:218–32.Google Scholar
- 8.Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:887.CrossRefGoogle Scholar
- 19.The Royal Children’s Hospital clinical practice guidelines for vancomycin. https://www.rch.org.au/clinicalguide/guideline_index/Vancomycin/. Accessed 27 May 2019.
- 23.Du L, Zukotynski K, Hsiao E, Zurakowski D, Treves ST, Grant F. Pediatric reference ranges for glomerular filtration rate determined by a single injection of Tc-99m DTPA. J Nucl Med. 2009;50:1375.Google Scholar
- 25.WHO Essential medicines and health products. https://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd_more/en/. Accessed 16 Apr 2019.
- 39.Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62:e02042.PubMedPubMedCentralGoogle Scholar
- 43.Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC(0-24) threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;61:e02535.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Hundeshagen G, Herndon DN, Capek KD, Branski LK, Voigt CD, Killion EA, Cambiaso-Daniel J, Sljivich M, De Crescenzo A, Mlcak RP, Kinsky MP, Finnerty CC, Norbury WB. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care. 2017;21:318.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Hoegy D, Goutelle S, Garnier N, Rénard C, Faure-Conter C, Bergeron C, Bertrand Y, Bleyzac N. Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology–oncology: prospective validation of a dosing regimen optimizing steady-state concentration. Fundam Clin Pharmacol. 2018;32:323–9.CrossRefPubMedGoogle Scholar